drugset / Trial / NCT00230282
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study was to evaluate the safety and efficacy of the combination of fludarabine and cyclophosphamide in previously untreated CLL patients. Participants will receive fludarabine and cyclophosphamide on days 1, 2, and 3 of six 28-day cycles.
Timeline
- Start
- 2004-07
- Primary completion
- 2010-12
- Completion
- 2011-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alemtuzumab | Monoclonal antibody | 30 mg | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 250 mg/m2 | Subcutaneous |
| Subject | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |